Viewing Study NCT03502616


Ignite Creation Date: 2025-12-26 @ 11:47 AM
Ignite Modification Date: 2025-12-26 @ 11:47 AM
Study NCT ID: NCT03502616
Status: COMPLETED
Last Update Posted: 2021-09-17
First Post: 2018-04-11
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)
Sponsor: Pfizer
Organization:

Study Overview

Official Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS)
Status: COMPLETED
Status Verified Date: 2021-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to determine if tofacitinib is safe and effective in subjects with active ankylosing spondylitis.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
AS OTHER Alias Study Number View
2018-000226-58 EUDRACT_NUMBER None View